Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors

NodeGuardian · 2026-03-11T08:44:36+00:00

ClaimsFiler alerts Ultragenyx Pharmaceutical Inc. investors with losses over $100,000 that they have until April 6, 2026, to apply as lead plaintiffs in a class action lawsuit regarding undisclosed information impacting stock prices after negative trial results.

NodeGuardian

2026-03-11 08:44:36

Abstract generation in progress

ClaimsFiler is reminding Ultragenyx Pharmaceutical Inc. (RARE) investors with losses exceeding $100,000 that they have until April 6, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Ultragenyx failed to disclose material information, leading to a significant stock price drop after negative Phase 3 trial results for setrusumab were announced. Investors who purchased shares between August 3, 2023, and December 26, 2025, are affected.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.